Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman at least 18 years old~* Diagnosis of metastatic colorectal cancer (mCRC)~* One and only one chemotherapy regimen for mCRC consisting of first-line 5-FU -based chemotherapy~* Radiologically documented disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria during treatment or within 6 months of last dose of first-line chemotherapy~* At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST~* Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2~* Paraffin-embedded tumor tissue from the primary tumor or metastasis available for central analyses~* Adequate hematologic, renal, and hepatic functions~* Negative pregnancy test within 72 hours of enrollment~* Other protocol-specified criteria may apply~Exclusion Criteria:~* History of or known presence of central nervous system (CNS) metastases~* History of another primary cancer within 5 years of randomization~* Prior irinotecan therapy~* Prior anti-epidermal growth factor receptor (EGFr) antibody therapy or treatment with small molecule EGFr inhibitors~* Any investigational agent or therapy within 30 days before randomization~* Known allergy or hypersensitivity to irinotecan, 5-FU or leucovorin~* History of interstitial lung disease or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan~* Active inflammatory bowel disease or other bowel disease causing chronic diarrhea~* Known positive tests for human immunodefiency virus (HIV), hepatitis C viris (HCV), acute or chronic active hepatitis B virus (HBV)~* Major surgery within 28 days of randomization or minor surgical procedure within 14 days of randomization~* Pregnant or breast-feeding~* Man or woman of child-bearing potential not consenting to use adequate contraceptive methods or abstinence during the course of the study and for 6 months after last study drug administration (women) or 1 month after last study drug administration (men)~* Other protocol-specified criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab Plus FOLFIRI (Type: EXPERIMENTAL): Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.
- FOLFIRI Alone (Type: ACTIVE_COMPARATOR): Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).